HC Wainwright Reaffirms Buy Rating for Krystal Biotech

HC Wainwright & Co. recently reiterated its buy rating on Krystal Biotech, Inc. (NasdaqGS: KRYS), setting a price target of $361. This reaffirmation came on June 16, 2026, as the company's shares traded around $324.75.

Analysts Set New Price Targets

On June 16, 2026, HC Wainwright maintained its buy rating for Krystal Biotech with a $361 price target. Citigroup also maintained a buy rating with a higher target of $378 on May 5, 2026. Evercore ISI Group, on the same day, kept its buy rating with a target of $300. Overall, the consensus among nine analysts is a strong buy, with a mean target price of $322.78.

Other Institutional Activity in Krystal Biotech

FMR LLC grew its holdings in Krystal Biotech by 24,359 shares, ending with 4,373,987 shares worth about $1.13 billion. BlackRock, Inc. added 2,639 shares, bringing its total to 3,940,456 shares valued at approximately $1.02 billion. Avoro Capital Advisors LLC held steady with 2,888,888 shares valued at about $746.26 million. Vanguard Portfolio Management LLC established a new position with 1,456,727 shares, valued at $376.3 million. Meanwhile, State Street Corp reduced its position by 27,869 shares, holding 1,314,434 shares worth around $339.54 million.

Krystal Biotech Stock Snapshot

Shares of NasdaqGS:KRYS are trading near $324.75. Krystal Biotech has a market cap of about $9.53 billion, a P/E ratio of 43.4, and a forward P/E of 32.1. The stock's 52-week range spans from $127.99 to $331.49, with a 50-day moving average of $290.80 and a 200-day moving average of $242.22. The company maintains a strong financial position with a current ratio of 9.46 and a quick ratio of 8.82.

Recent Earnings

Krystal Biotech reported revenue of $417.3 million, reflecting a growth rate of 31.9%. The company's net margin stands at 53.9%, with a return on equity of 19.9%. Earnings per share (EPS) were noted at $7.45, and the next earnings report is scheduled for August 3, 2026.

Insider Buying and Selling at Krystal Biotech, Inc.

Recent planned insider sales included Krishnan Suma, President of R&D, who sold 25,000 shares on June 4, 2026, at an average price of $308.12. Krishnan Krish, President and CEO, also sold 25,000 shares on the same day at a similar price. EVP and General Counsel Thomas John Charles sold 642 shares on May 26, 2026, at $302.03, all under Rule 10b5-1 plans.

About Krystal Biotech

Krystal Biotech, Inc. is a biotechnology firm based in Pittsburgh, Pennsylvania. Founded in 2016, the company focuses on developing genetic medicines for diseases with high unmet needs. Its flagship product, VYJUVEK, is used to treat dystrophic epidermolysis bullosa, and it has several other candidates in various stages of clinical trials targeting conditions like cystic fibrosis and Hailey-Hailey disease. Led by CEO Krish S. Krishnan, the company employs about 295 people.

Bottom Line

HC Wainwright's reiterated buy rating and $361 price target underscore confidence in Krystal Biotech's growth prospects. Investors often monitor such analyst actions to gauge market sentiment, though it's important to remember that these ratings are based on past data and projections. As always, it's crucial to consider multiple factors when assessing a stock's potential.